The study is to investigate the bone health effect from E. serra by osteoclast-like RAW264.7 cells. Results showed that no cytotoxicity and proliferation in RAW264.7 and osteoclast-like RAW264.7 cells (added RANKL and M-CSF). The activity of pro-inflammatory factor (IL-6 and IL-1β) and anti-inflammatory factor (IL-10) assay showed that enzyme hydrolyzate can inhibited IL-1β activity to 46.6-79.5% from E. serra. 5-50 μg/mL enzyme hydrolyzate inhibited the formation of multinuclei in osteoclast-like RAW264.7 cells with a dose-dependent manner. The expression of calcitonin receptor were decreased to 53-73% (compared with positive control) with enzyme hydrolysate ≧ 5 mg/mL from E. serra. When enzyme hydrolysate ≧ 31.25 μg/mL, there were indicated that enzyme hydrolysate inhibit the production of osteoclasts in bone resorption assay. The mRNA expression of NFATc1、RANK and DC-STAMP were showed significantly different (compared with positive control) with 250-500 μg/mL enzyme hydrolysate. 50-500 μg/mL enzyme hydrolysate were showed significantly different in the antiapoptotic gene mRNA expression of BCL-2 and proapoptotic gene mRNA expression of BAX. In view of the above, enzyme hydrolysate can cause osteoclast cells apoptosis, and can inhibited osteoclast activity, with the potential of bone health from E. serra .